Explore our blog
2028 and Beyond: Winning JCA in Rare Diseases
Jenny Chen, MSc | Senior Director, Precision AQ Emma Hawe, MSc | Senior Vice President, Managing Director, Precision AQ...
Pharma’s Next Moves: Adapting to the FTC’s PBM Overhaul
Eve Jamali| SVP, Managing Director, US Access Strategy & Analytics Andrew Cournoyer | SVP, Head of Access Experience...
Cellular Therapies in Hematologic Malignancies: Trends & Market Access Implications Across Care Settings
Madeline Waldron, PharmD, BCOP | Vice President, Clinical Oncology Solutions